A Photo-Activatable Peptide Mimicking Functions of Apolipoprotein A-I
Tóm tắt
Từ khóa
Tài liệu tham khảo
1) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. <i>Am. J. Med.</i>, <b>62</b>, 707–714 (1977).
2) Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. <i>Atherosclerosis</i>, <b>124</b> (Suppl.), S11–S20 (1996).
3) Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. <i>Circulation</i>, <b>108</b>, 2751–2756 (2003).
4) Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. <i>J. Lipid Res.</i>, <b>42</b>, 1308–1317 (2001).
5) Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A. HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. <i>Arterioscler. Thromb. Vasc. Biol.</i>, <b>17</b>, 2158–2166 (1997).
6) Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. <i>Life Sci.</i>, <b>55</b>, 1815–1821 (1994).
7) Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. <i>J. Clin. Invest.</i>, <b>85</b>, 1234–1241 (1990).
8) Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto YI, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. <i>Arterioscler. Thromb. Vasc. Biol.</i>, <b>15</b>, 1882–1888 (1995).
9) Recio C, Maione F, Iqbal AJ, Mascolo N, De Feo V. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease. <i>Front. Pharmacol.</i>, <b>7</b>, 526 (2017).
10) Stoekenbroek RM, Stroes ES, Hovingh GK. ApoA-I mimetics. <i>Handb. Exp. Pharmacol.</i>, <b>224</b>, 631–648 (2015).
11) Lund-Katz S, Phillips MC. High density lipoprotein structure-function and role in reverse cholesterol transport. <i>Subcell. Biochem.</i>, <b>51</b>, 183–227 (2010).
12) Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. <i>J. Lipid Res.</i>, <b>48</b>, 2453–2462 (2007).
13) Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D’Souza W, Sviridov D, Remaley AT. Asymmetry in the lipid affinity of bihelical amphipathic peptides: a structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. <i>J. Biol. Chem.</i>, <b>283</b>, 32273–32282 (2008).
14) D’Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, Moore XL, Chin-Dusting J, Remaley AT, Sviridov D. Structure/function relationships of apolipoprotein A-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. <i>Circ. Res.</i>, <b>107</b>, 217–227 (2010).
15) Conroy T, Jolliffe KA, Payne RJ. Synthesis of <i>N</i>-linked glycopeptides <i>via</i> solid-phase aspartylation. <i>Org. Biomol. Chem.</i>, <b>8</b>, 3723–3733 (2010).
16) Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, Phillips MC, Lund-Katz S. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. <i>J. Lipid Res.</i>, <b>43</b>, 1688–1700 (2002).
17) Nagao K, Hata M, Tanaka K, Takechi Y, Nguyen D, Dhanasekaran P, Lund-Katz S, Phillips MC, Saito H. The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles. <i>Biochim. Biophys. Acta - Mol. Cell Biol. Lipids</i>, <b>1841</b>, 80–87 (2014).
18) Sparks DL, Lund-Katz S, Phillips MC. The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. <i>J. Biol. Chem.</i>, <b>267</b>, 25839–25847 (1992).
19) Okuhira K, Tsujita M, Yamauchi Y, Abe-Dohmae S, Kato K, Handa T, Yokoyama S. Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. <i>J. Lipid Res.</i>, <b>45</b>, 645–652 (2004).
20) Vaughan AM, Oram JF. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. <i>J. Lipid Res.</i>, <b>44</b>, 1373–1380 (2003).
21) Venkatachalapathi YV, Phillips MC, Epand RM, Epand RF, Tytler EM, Segrest JP, Anantharamaiah GM. Effect of end group blockage on the properties of a class A amphipathic helical peptide. <i>Proteins Struct. Funct. Bioinforma.</i>, <b>15</b>, 349–359 (1993).
22) Egashira M, Gorbenko G, Tanaka M, Saito H, Molotkovsky J, Nakano M, Handa T. Cholesterol modulates interaction between an amphipathic class A peptide, Ac-18A-NH2, and phosphatidylcholine bilayers. <i>Biochemistry</i>, <b>41</b>, 4165–4172 (2002).
23) Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. <i>J. Lipid Res.</i>, <b>51</b>, 1496–1503 (2010).
24) Amar MJA, D’Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. <i>J. Pharmacol. Exp. Ther.</i>, <b>334</b>, 634–641 (2010).
25) Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties <i>in vivo</i> and <i>in vitro.</i> <i>Arterioscler. Thromb. Vasc. Biol.</i>, <b>30</b>, 246–252 (2010).
26) Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. <i>Int. J. Cancer</i>, <b>130</b>, 1071–1081 (2012).
27) Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, Grijalva V, Springstead JR, Palgnachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, Farias-Eisner R, Reddy ST, Fogelman AM. A novel approach to oral apoA-I mimetic therapy. <i>J. Lipid Res.</i>, <b>54</b>, 995–1010 (2013).
28) Iwata A, Miura SI, Zhang B, Imaizumi S, Uehara Y, Shiomi M, Saku K. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. <i>Atherosclerosis</i>, <b>218</b>, 300–307 (2011).
29) Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. <i>J. Lipid Res.</i>, <b>47</b>, 107–114 (2006).
30) Ellis-Davies GCR. Caged compounds: Photorelease technology for control of cellular chemistry and physiology. <i>Nat. Methods</i>, <b>4</b>, 619–628 (2007).